Eko Low Ejection Fraction Tool (ELEFT) vs Cardiomo

Eko Low Ejection Fraction Tool (ELEFT) integrates with existing Eko digital stethoscopes, making it a seamless addition to a clinician's routine physical exam. The results are provided quickly, in approximately 15 seconds, during the point of care. Cardiomo, while offering a user-friendly wearable patch and mobile app, requires patients to wear a device continuously, which might be less convenient for some users compared to a quick in-clinic screening.

ELEFT is an FDA-cleared AI algorithm specifically designed for early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams. It has undergone clinical validation in multi-site prospective studies, demonstrating robust performance in detecting low ejection fraction. Cardiomo offers continuous vital sign monitoring and AI-powered disease detection, but its FDA approval status for its AI algorithms is not explicitly stated in the provided information, and while it mentions clinical studies, specific validation outcomes for its disease detection algorithms are less detailed.

Both Eko Low Ejection Fraction Tool (ELEFT) and Cardiomo require contacting their respective sales teams for specific pricing, indicating a lack of public pricing transparency. ELEFT is part of an enterprise platform, suggesting a higher cost for individual clinicians, while Cardiomo previously offered a device with a monthly subscription, but current pricing is unavailable. Without transparent pricing, it is difficult to definitively assess which offers better value.

Eko Low Ejection Fraction Tool (ELEFT) is explicitly stated to be part of Eko's SENSORAu2122 platform, an enterprise solution designed for health systems to scale AI-powered cardiac disease detection across specialties. This indicates a strong focus on enterprise deployment and integration. Cardiomo, while offering a cloud-based platform and HIPAA compliance, appears to be more focused on individual patient monitoring and remote care, with less emphasis on broad enterprise-level deployment across health systems.

Eko Low Ejection Fraction Tool (ELEFT) represents a significant innovation by integrating AI-powered heart failure detection into a routine stethoscope exam, making early screening more accessible at the point of care. This transforms a traditional medical device into an AI-powered diagnostic tool. Cardiomo's continuous remote monitoring with a wearable device and AI analysis is innovative in its approach to proactive patient care, but ELEFT's integration into an existing, widely used clinical workflow for early disease detection during a standard physical exam gives it an edge in terms of disruptive innovation within the clinical setting.

Eko Health provides a comprehensive support system, including a dedicated Help Center with user manuals and FAQs, live Q&A sessions, 1:1 phone calls, and email support, specifically catering to both individual users and enterprise institutions. Cardiomo's documentation and support details are less transparent in the provided information, with no specific help center or detailed support channels publicly advertised, making Eko the stronger contender in this dimension.